Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.
Total raised: $25M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | 3E Biovent... | 3ebiovc.co... |
| - | DHVC | dh.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.05.2018 | Series B | $25M | - |
Mentions in press and media 5
| Date | Title | Description |
| 03.05.2018 | Term Sheet — Thursday, May 3 | TWO BANKRUPTCIES AND A WEDDING Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop SHUT OUT: In case you missed this, Birchbox is going through some stuff. Early investor Viking Global has... |
| 02.05.2018 | Refuge Biotechnologies Completes $25M Series B Financing | Refuge Biotechnologies, Inc., a Menlo Park, CA-based company leveraging gene engineering technologies to develop intelligent cell therapeutics programmed to make decisions inside of patients, closed a $25m Series B funding round. The round ... |
| 02.05.2018 | Sequoia China co-leads $25m Series B in US biotech firm Refuge | Premium Venture capital firm Sequoia Capital China has co-led a $25-million Series B funding round in Refuge Biotechnologies, a California-based biotech startup that leverages gene engineering technologies to develop therapeutic cells that ... |
| 02.05.2018 | Refuge Biotechnologies Nets $25M Series B | MENLO PARK, CA, Refuge Biotechnologies announced the closing of a $25 million Series B investment round. >> Click here for more funding data on Refuge Biotechnologies >> To export Refuge Biotechnologies funding data to PDF a... |
| 02.05.2018 | Chinese investors back Refuge Bio’s $25M B round as it steers gene engineering tech to an IND | A group of Chinese investors led by 3SBio and Sequoia China are bankrolling the next leg of development at Refuge Biotechnologies, a Bay Area biotech that’s been using CRISPR technology to control gene expression. Stanley Q... |